Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 3/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.70 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoxeridine SCHEMBL908077 | 0.87 | OPRM1 (0.71) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.86 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Pheneridine SCHEMBL1922392 | 0.86 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL9064841 | 0.85 | KCNA3 (0.73) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11708747 | 0.84 | KCNA3 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.84 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL9064487 | 0.84 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11282136 | 0.83 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11601769 | 0.83 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712071 | 0.83 | OPRM1 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| EP-3423034-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| CN-109069419-A | Abuse resistant drugs composition | G.L.制药有限责任公司 | 2018-12-21 | — | — | CN | claimed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | claimed |
| EP-3129028-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| CN-106413717-A | Pharmaceutical compositions | 查尔斯顿实验室公司 | 2017-02-15 | — | — | CN | claimed |
| US-20150313846-A1 | PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM | FLAMEL IRELAND LIMITED (IE) | 2015-11-05 | — | — | US | claimed |
| WO-2007054378-A1 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM | FLAMEL TECHNOLOGIES (FR) | 2007-05-18 | — | — | WO | claimed |
| WO-2006133733-A1 | ORAL DOSAGE FORM COMPRISING AN ANTIMISUSE SYSTEM | FLAMEL TECHNOLOGIES (FR) | 2006-12-21 | — | — | WO | claimed |
| WO-2006134018-A2 | ORAL DOSAGE FORM COMPRISING AN ANTIMISUSE SYSTEM | FLAMEL TECHNOLOGIES (FR) | 2006-12-21 | — | — | WO | claimed |
| WO-2006089843-A2 | ANTI-MISUSE MICROPARTICULATE ORAL DRUG FORM | FLAMEL TECHNOLOGIES (FR) | 2006-08-31 | — | — | WO | claimed |
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |